{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Established Pharmacologic Class [EPC]" in comments (approximate match)
Status:
US Approved Rx
(2004)
Source:
BLA125103
(2004)
Source URL:
First approved in 2004
Source:
BLA125103
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2004)
Source:
NDA021060
(2004)
Source URL:
First approved in 2004
Source:
NDA021060
Source URL:
Class:
PROTEIN
Conditions:
Ziconotide (PRIALT; SNX-111) is a neuroactive peptide, which was approved by FDA in 2004 for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Ziconotide acts as a selective N-type voltage-gated calcium channel blocker, which leads to a blockade of excitatory neurotransmitter release from the primary afferent nerve terminals.
Status:
US Approved Rx
(2004)
Source:
BLA125084
(2004)
Source URL:
First approved in 2004
Source:
BLA125084
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
Source:
BLA021106
(2003)
Source URL:
First approved in 2003
Source:
BLA021106
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
Source:
BLA103979
(2003)
Source URL:
First approved in 2003
Source:
BLA103979
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2025)
Source:
BLA761399
(2025)
Source URL:
First approved in 2003
Source:
BLA103976
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2003)
Source:
BLA125058
(2003)
Source URL:
First approved in 2003
Source:
BLA125058
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2002)
Source:
BLA125019
(2002)
Source URL:
First approved in 2002
Source:
BLA125019
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2022)
Source:
BLA761173
(2022)
Source URL:
First approved in 2002
Source:
BLA125031
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2002)
Source:
BLA103964
(2002)
Source URL:
First approved in 2002
Source:
BLA103964
Source URL:
Class:
PROTEIN
